22 Aug Astellas
At Astellas, we aim to discover, develop and deliver breakthrough gene therapies with life-changing VALUE for patients across many disease areas. We are developing one of the world’s most robust pipelines of gene therapies for genetic disorders and an end-to-end gene therapy powerhouse with industry-leading discovery, development, manufacturing and commercial capabilities. We have two candidates in clinical development for rare neuromuscular diseases: AT845, in Phase 1/2 for Pompe disease and AT132 for X-linked myotubular myopathy, currently on clinical hold. We are also working to build our portfolio across other indications including A2016 for cardiac complications associated with Friedreich ataxia, which has received FDA IND clearance. Alongside our partners, clinicians, regulatory authorities and patient communities, we strive to overcome complex challenges across the value chain so we can deliver the promise of ground-breaking science to patients.
